Our study aimed to establish the real-world effectiveness and safety profiles of goserelin 10.8-mg depot in Chinese patients from 29 study centers with hormone treatment-naïve, localized, or locally advanced prostate cancer and to examine the real-world testing patterns of serum testosterone and prostate-specific antigen (PSA) while under goserelin treatment. Here, KLK3 is linked to prostate cancer.